BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 29193056)

  • 1. Identification of a novel fusion gene HMGA2-EGFR in glioblastoma.
    Komuro A; Raja E; Iwata C; Soda M; Isogaya K; Yuki K; Ino Y; Morikawa M; Todo T; Aburatani H; Suzuki H; Ranjit M; Natsume A; Mukasa A; Saito N; Okada H; Mano H; Miyazono K; Koinuma D
    Int J Cancer; 2018 Apr; 142(8):1627-1639. PubMed ID: 29193056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Constitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants.
    Park AK; Francis JM; Park WY; Park JO; Cho J
    Oncotarget; 2015 Apr; 6(11):8839-50. PubMed ID: 25826094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.
    Mellinghoff IK; Wang MY; Vivanco I; Haas-Kogan DA; Zhu S; Dia EQ; Lu KV; Yoshimoto K; Huang JH; Chute DJ; Riggs BL; Horvath S; Liau LM; Cavenee WK; Rao PN; Beroukhim R; Peck TC; Lee JC; Sellers WR; Stokoe D; Prados M; Cloughesy TF; Sawyers CL; Mischel PS
    N Engl J Med; 2005 Nov; 353(19):2012-24. PubMed ID: 16282176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glioblastoma stem-like cell lines with either maintenance or loss of high-level EGFR amplification, generated via modulation of ligand concentration.
    Schulte A; Günther HS; Martens T; Zapf S; Riethdorf S; Wülfing C; Stoupiec M; Westphal M; Lamszus K
    Clin Cancer Res; 2012 Apr; 18(7):1901-13. PubMed ID: 22316604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development.
    Brown KE; Chagoya G; Kwatra SG; Yen T; Keir ST; Cooter M; Hoadley KA; Rasheed A; Lipp ES; Mclendon R; Ali-Osman F; Bigner DD; Sampson JH; Kwatra MM
    J Neurochem; 2015 Jun; 133(5):730-8. PubMed ID: 25598002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.
    Haas-Kogan DA; Prados MD; Tihan T; Eberhard DA; Jelluma N; Arvold ND; Baumber R; Lamborn KR; Kapadia A; Malec M; Berger MS; Stokoe D
    J Natl Cancer Inst; 2005 Jun; 97(12):880-7. PubMed ID: 15956649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.
    Lee JC; Vivanco I; Beroukhim R; Huang JH; Feng WL; DeBiasi RM; Yoshimoto K; King JC; Nghiemphu P; Yuza Y; Xu Q; Greulich H; Thomas RK; Paez JG; Peck TC; Linhart DJ; Glatt KA; Getz G; Onofrio R; Ziaugra L; Levine RL; Gabriel S; Kawaguchi T; O'Neill K; Khan H; Liau LM; Nelson SF; Rao PN; Mischel P; Pieper RO; Cloughesy T; Leahy DJ; Sellers WR; Sawyers CL; Meyerson M; Mellinghoff IK
    PLoS Med; 2006 Dec; 3(12):e485. PubMed ID: 17177598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth and metastasis suppression of glioma xenografts expressing exon 4-deletion variant of epidermal growth factor receptor by monoclonal antibody CH12-mediated receptor degradation.
    Wang H; Shi B; Zhang Q; Jiang H; Hu S; Kong J; Yao M; Yang S; Li Z
    FASEB J; 2012 Jan; 26(1):73-80. PubMed ID: 21917986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity.
    Nishikawa R; Ji XD; Harmon RC; Lazar CS; Gill GN; Cavenee WK; Huang HJ
    Proc Natl Acad Sci U S A; 1994 Aug; 91(16):7727-31. PubMed ID: 8052651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines.
    Bax DA; Gaspar N; Little SE; Marshall L; Perryman L; Regairaz M; Viana-Pereira M; Vuononvirta R; Sharp SY; Reis-Filho JS; Stávale JN; Al-Sarraj S; Reis RM; Vassal G; Pearson AD; Hargrave D; Ellison DW; Workman P; Jones C
    Clin Cancer Res; 2009 Sep; 15(18):5753-61. PubMed ID: 19737945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas.
    Narita Y; Nagane M; Mishima K; Huang HJ; Furnari FB; Cavenee WK
    Cancer Res; 2002 Nov; 62(22):6764-9. PubMed ID: 12438278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.
    Ramnarain DB; Park S; Lee DY; Hatanpaa KJ; Scoggin SO; Otu H; Libermann TA; Raisanen JM; Ashfaq R; Wong ET; Wu J; Elliott R; Habib AA
    Cancer Res; 2006 Jan; 66(2):867-74. PubMed ID: 16424019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor.
    Nagane M; Narita Y; Mishima K; Levitzki A; Burgess AW; Cavenee WK; Huang HJ
    J Neurosurg; 2001 Sep; 95(3):472-9. PubMed ID: 11565870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amplified HMGA2 promotes cell growth by regulating Akt pathway in AML.
    Tan L; Wei X; Zheng L; Zeng J; Liu H; Yang S; Tan H
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):389-99. PubMed ID: 26319392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SHP-2-dependent mitogen-activated protein kinase activation regulates EGFRvIII but not wild-type epidermal growth factor receptor phosphorylation and glioblastoma cell survival.
    Zhan Y; O'Rourke DM
    Cancer Res; 2004 Nov; 64(22):8292-8. PubMed ID: 15548697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.
    Xing WJ; Zou Y; Han QL; Dong YC; Deng ZL; Lv XH; Jiang T; Ren H
    Clin Exp Pharmacol Physiol; 2013 Jan; 40(1):13-21. PubMed ID: 23110505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-7 inhibits glioblastoma growth by simultaneously interfering with the PI3K/ATK and Raf/MEK/ERK pathways.
    Liu Z; Jiang Z; Huang J; Huang S; Li Y; Yu S; Yu S; Liu X
    Int J Oncol; 2014 May; 44(5):1571-80. PubMed ID: 24603851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of cytoplasmic-domain substituted epidermal growth factor receptor inhibits tumorigenicity of EGFR-overexpressed human glioblastoma multiforme.
    Liu KJ; Chen CT; Hu WS; Hung YM; Hsu CY; Chuang BF; Juang SH
    Int J Oncol; 2004 Mar; 24(3):581-90. PubMed ID: 14767543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRIM71 suppresses tumorigenesis via modulation of Lin28B-let-7-HMGA2 signaling.
    Yin J; Kim TH; Park N; Shin D; Choi HI; Cho S; Park JB; Kim JH
    Oncotarget; 2016 Nov; 7(48):79854-79868. PubMed ID: 27821801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The transcriptional modulator HMGA2 promotes stemness and tumorigenicity in glioblastoma.
    Kaur H; Ali SZ; Huey L; Hütt-Cabezas M; Taylor I; Mao XG; Weingart M; Chu Q; Rodriguez FJ; Eberhart CG; Raabe EH
    Cancer Lett; 2016 Jul; 377(1):55-64. PubMed ID: 27102002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.